Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04796779 · ClinicalTrials.gov registry record · NA
The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
A NA study, sponsored by Marc Breton.
- Completed
- Registry status
- NA
- Development phase
- 102
- Enrollment target
NCT04796779 is a NA study that has completed, run by Marc Breton. The registered enrollment target is 102 participants.
The verdict
NCT04796779, a NA study, has completed, sponsored by Marc Breton.
- COMPLETED
- Registry status
- NA
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes called blood sugar) control.
Interventions
- DEVICE Tandem t:slim X2 with Control-IQ Technology Pro
- DEVICE Standard Care (SC)
- DEVICE Tandem t:slim X2 with Control-IQ Technology V1.5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2022-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04796779
The ClinicalTrials.gov registry entry for NCT04796779 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marc Breton, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tandem t:slim X2 with Control-IQ Technology Pro is the first listed.
NCT04796779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04796779 about?
NCT04796779 is a clinical study titled "The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes". The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes called blood sugar) control.
What is the current status of trial NCT04796779?
This trial is currently completed. It is a NA study. The enrollment target is 102 participants. The study started on 2021-04-21. Estimated completion is 2022-07-31.
What interventions are being tested in trial NCT04796779?
The interventions under investigation include: Tandem t:slim X2 with Control-IQ Technology Pro (DEVICE), Standard Care (SC) (DEVICE), Tandem t:slim X2 with Control-IQ Technology V1.5 (DEVICE).
Who is sponsoring clinical trial NCT04796779?
This trial is sponsored by Marc Breton, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.